CBG and CBN: When the Premium Price May (and May Not) Be Worth It

Products featuring cannabigerol (CBG) or cannabinol (CBN) often cost more than conventional cannabis products. That premium can be understandable: these cannabinoids are typically present in smaller amounts than THC or CBD, and producing a product with a meaningful, consistent concentration may require selective breeding, specialized extraction, or additional testing. But a higher price does not automatically mean greater health benefits.

Whether CBG or CBN is worth the cost depends largely on what you want from the product, how much evidence supports that use, and whether the product’s contents have been independently verified.

What are CBG and CBN?

CBG and CBN are naturally occurring cannabinoids produced by the cannabis plant. They are sometimes called “minor cannabinoids,” a term that generally reflects how little they have been studied compared with THC and CBD—not necessarily that they are unimportant or always present in trace amounts.

CBG is formed from cannabigerolic acid, or CBGA, a precursor involved in the plant’s production of several other cannabinoids, including THC and CBD. Because most cannabis plants convert much of their CBGA into other compounds as they mature, CBG-rich flower can require selective cultivation or harvesting at a particular stage.

CBN is formed largely as THC breaks down through exposure to oxygen, light, and heat. Although CBN can occur in many cannabis products, it is usually present at relatively low levels unless a product has been specifically formulated or processed to contain more of it. CBN is often marketed as a sleep aid, but the idea that it is reliably sedating remains less certain than advertising commonly suggests.

What does the research show?

The strongest evidence for CBG and CBN is still limited compared with the much larger research base on THC and CBD. Laboratory and animal studies have identified possible effects involving inflammation, pain, mood, and sleep, but results from those models cannot be assumed to predict benefits in people.

Human research on CBG is beginning to emerge. In a 2024 double-blind, placebo-controlled crossover study of 34 healthy adults, a 20-milligram dose of hemp-derived CBG was associated with short-term reductions in self-reported anxiety and stress compared with placebo. The study did not test people with an anxiety disorder, did not examine long-term use, and was not evidence that CBG treats a medical condition. A separate 2026 dose-escalation study in 12 healthy adults found that oral CBG was generally well tolerated after single doses of 25 to 200 milligrams, while producing few consistent subjective or physiological effects.

Evidence for CBN and sleep is similarly mixed. A 2023 randomized trial involving 293 adults with poor self-rated sleep found that 20 milligrams of CBN reduced the number of nighttime awakenings and overall sleep disturbance, but its improvement in overall sleep quality did not reach statistical significance. Adding CBD did not clearly produce a larger benefit. In a small 2026 crossover trial of 20 adults with diagnosed insomnia, a single 300-milligram dose of CBN improved some secondary sleep measures, but it did not significantly improve the study’s primary outcome: wake time after falling asleep. The researchers said larger and longer trials are needed.

These findings suggest that CBG and CBN are worth studying—not that their therapeutic value has been established. There is currently no strong clinical evidence that either cannabinoid treats arthritis, inflammatory bowel disease, epilepsy, multiple sclerosis, cancer pain, or anxiety disorders. Claims about the “entourage effect,” in which combinations of cannabinoids and terpenes are presumed to work better than isolated compounds, remain biologically plausible but insufficiently demonstrated in well-controlled human trials for most specific conditions.

Why do CBG and CBN products cost more?

Price differences can result from several factors:

• CBG-rich plants may produce less of the desired cannabinoid than conventional THC- or CBD-dominant varieties.
• CBN may be produced through additional processing rather than simply harvested from ordinary flower.
• Purification, formulation, stability testing, and independent laboratory analysis add manufacturing costs.
• Products aimed at a small, specialized market may carry higher margins.

However, a premium price is not proof of superior quality. A product may be expensive because of branding, scarcity, or marketing rather than because it contains more effective or better-tested ingredients.

What should shoppers look for?

Start with a batch-specific certificate of analysis from an independent laboratory. It should show the amount of CBG, CBN, THC, CBD, and other relevant cannabinoids, along with testing for pesticides, heavy metals, solvents, and microbial contamination. Products labeled “hemp,” “full spectrum,” or “nonintoxicating” may still contain THC or other compounds.

The National Center for Complementary and Integrative Health notes that cannabinoid products can differ substantially from their labels and that research on many uses remains at an early stage. The U.S. Food and Drug Administration also warns that most over-the-counter cannabis-derived products have not undergone the review required for approved medicines.

People who take prescription drugs should also ask a healthcare professional before using cannabinoid products. Cannabinoids may affect alertness and may interact with other medications. Anyone who is pregnant, breastfeeding, under legal age, or being treated for a serious medical condition should seek individualized medical advice rather than relying on a product label or promotional claim.

The bottom line

CBG or CBN may be worth paying extra for if you have a specific reason to try one, can afford the experiment, and choose a product with reliable independent testing. The evidence is most promising—but still preliminary—for short-term effects involving anxiety, stress, or sleep.

For broad claims about inflammation, chronic pain, seizures, or disease treatment, the current evidence does not justify assuming that a CBG- or CBN-rich product will outperform a less expensive cannabinoid product or an established medical treatment. The premium may buy a more specialized formulation, but it does not yet buy certainty that the product will work.